Purpose Built for Refractory Angina
Minimally-invasive frontline therapy designed to swiftly relieve refractory angina (RA) symptoms.
A-FLUX Reducer Systemᵀᴹ
with Swiftcellᵀᴹ Technology
Millions of refractory angina patients are left with no options for treatment
Millions of RA patients worldwide suffer from persistent pressure, tightness, and chest pain, with no viable options for relief.¹ Living with RA means constant discomfort and reduced well-being. It’s time for a more effective treatment.
A-FLUX Reducer Systemᵀᴹ
Minimally-invasive interventional therapy to swiftly relieve RA symptoms
SwiftCell Technology enables more immediate patient response
Delivery system provides reliable, straightforward delivery of reducer implant
Redistributes oxygen supply to achieve RA symptom relief
Designed to facilitate swift and targeted therapy
Variable Cell Structure
Optimized to redistribute cardiac blood flow immediately upon delivery
Narrowing designed to provide robust performance, regardless of anatomy
Conforms seamlessly to coronary sinus (CS) anatomy, ensuring proper placement and long-term retention
The incredible team behind vahaticor
FOUNDER AND CHAIRMAN
Kevin Van Bladel
HEAD OF CORPORATE DEVELOPMENT
Howard was the Founder and CEO of VitalWear, a leader in thermal and compression therapy systems. In 2009, VitalWear was named on the INC 500 list of fastest growing private companies and on the San Francisco Business Times Fast 100. He has served in management roles at Johnson & Johnson, Zeiss, CooperVision, and Bio-Rad Laboratories and various startup companies in the Bay Area.
He was Chairman of the Medical Device and Digital Health screening committee of Life Science Angels and was the first Entrepreneur in Residence at the University of San Francisco Innovation Ventures group. Mr. Edelman advises a variety of medical device and biotech companies (iDentical, Karuna Labs, Watershed Medical, Pluto Medical, and Carbon Trainer) and sat on the Research Committee for the Juvenile Diabetes Research Foundation (JDRF). Howard is currently Adjunct Faculty in the Graduate School of Management at the University of San Francisco and holds a B.S. in Biomedical Engineering from Boston University.
An inventor at heart, Marwan works closely with R&D teams and has been a part of several first-generation medical device product launches. He is genuinely passionate about empowering the people around him and driving global medical innovation. Marwan holds a B.S. in Mechanical Engineering from the University of Minnesota and an MBA in Finance from McGill University.
Kevin is a distinguished medical technology leader with an impressive career spanning over three decades. Currently, he serves as Chief Technology Officer at VahatiCor Inc., leveraging his strong skills in business analysis, research, project management, and R&D.
Kevin's career includes a 13-year tenure at BioVentrix, where he held the positions of Sr VP of Product & Therapeutic Development and VP of R&D. His expertise in engineering has been demonstrated in various roles at Apsara Medical, BaroSense Inc., Sanarus Medical, Reflow Inc., General Surgical Innovations, Menlo Care (Acquired by J&J), and Mentor Corporation. Kevin holds a B.S. in Physics from Caltech.
Michael is an accomplished senior corporate finance and strategic advisory professional with significant experience and a successful track record working with companies in the healthcare industry, with a focus on the medical technology and device sector. Throughout his 25-year investment banking career, Michael has applied his extensive financial expertise to foster growth in both early and late-stage companies. Michael serves as President of SAJ Advisors, Inc. He has previously held roles at Brean Capital, Landmark Ventures, BMO Capital Markets, Banc of America Securities, and Paine Webber. Michael holds a Bachelor of Commerce (Honors) in Finance from the University of Manitoba and an MBA from Columbia Business School.
about the company
A Commitment to Patient-Centric Innovation
At VahatiCor, Inc., a member of the T45 Labs portfolio, we strive to advance the medical technology landscape by creating innovative solutions that address unmet clinical needs and elevate the standard of care. Our goal is to transform patients’ lives worldwide, one breakthrough at a time.
Refractory angina (RA) is a debilitating condition that can profoundly impact a patient’s health, happiness, and overall quality of life. We recognize the challenges those living with RA face, and we’re dedicated to making a difference.
Our approach to frontline interventional treatment for RA focuses on rapidly providing relief and empowering patients to reclaim their daily lives. We aim to restore vitality and well-being to those affected by this challenging condition by providing an effective and efficient treatment option.
1. Refractory Angina research report. Delve Insight Business Research, July 2021.